Human adipose-derived cells: an update on the transition to clinical translation. (March 2012)

• Record Type: Journal Article
• Authors: Gimble, Jeffrey M; Bunnell, Bruce A; Guilak, Farshid
• Is Part Of: Regenerative medicine. Volume 7:Number 2(2012)
• Page Start: 225
• Page End: 235
• Publication Date: 2012-03
• Subjects: adipose -- adipose stromal/stem cell -- autoimmune -- bone repair -- clinical translation -- cosmetic surgery -- ischemic injury -- myocardial infarction -- stromal vascular fraction; Cellular therapy -- Periodicals; Stem cells -- Transplantation -- Periodicals; Degeneration (Pathology) -- Treatment -- Periodicals; Regeneration (Biology) -- Periodicals; 611.018
• DOI: 10.2217/rme.11.119
• Languages: English
• ISSNs: 1746-0751

Abstract

The pace of discovery involving adipose-derived cells continues to accelerate at both the preclinical and clinical translational levels. Adipose tissue is a source of freshly isolated, heterogeneous stromal vascular fraction cells and culture-expanded, adherent and relatively homogeneous adipose stromal/stem cells. Both populations display regenerative capacity in soft and hard tissue repair, ischemic insults and autoimmune diseases. While their major mechanism of action has been attributed to both direct lineage differentiation and/or paracrine factor release, current evidence favors a paracrine mechanism. Over 40 clinical trials using adipose-derived cells conducted in 15 countries have been registered with the NIH, the majority of which are Phase I or Phase I/II safety studies. This review focuses on the literature of the past 2 years in order to assess the status of clinical and preclinical studies on adipose-derived cell therapies for regenerative medicine.